Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692

Kazuhiro Iwase, B. Mark Evers, Mark Hellmich, Hong Jin Kim, Shunichi Higashide, Danielle Gully, James C. Thompson, Courtney Townsend

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

BACKGROUND. Recently, a nonpeptide neurotensin (NT) receptor antagonist, SR48692, was developed that selectively antagonizes the high affinity, biologically active NT binding site. The effect of SR48692 on NT-mediated growth of a human pancreatic carcinoma, MIA PaCa-2, was determined both in vitro and in vivo. METHODS. 125I-NT binding and Northern blot analyses were performed for evaluation of the NT receptor in MIA PaCa-2 cells. Intracellular calcium ([Ca2+l(i)) mobilization and inositol phosphate (IP3) levels were measured. Cell growth studies were performed by counting cell numbers. Athymic nude mice were inoculated with MIA PaCa-2 cells and randomized into four groups to receive either vehicle (NT or SR48692) or NT + SR48692. RESULTS. MIA PaCa-2 cells possess both a high affinity, SR48692- sensitive and a levocabastine-insensitive NT binding site; Northern blot analysis demonstrated expression of the NT receptor. SR48692 inhibited [Ca2+](i) mobilization, IP3 turnover, and MIA PaCa-2 cell growth induced by NT in a dose-dependent fashion. In in vivo experiments, NT significantly increased the size, weight, and DNA and protein content of xenografted MIA PaCa-2 tumors; SR48692 inhibited the effect of NT. CONCLUSIONS. The novel NT receptor antagonist SR48692 will be a valuable agent to delineate further the cellular mechanisms responsible for peptide-mediated growth of normal and neoplastic gut tissues.

Original languageEnglish (US)
Pages (from-to)1787-1793
Number of pages7
JournalCancer
Volume79
Issue number9
DOIs
StatePublished - May 1 1997

Fingerprint

Neurotensin Receptors
Neurotensin
Growth
levocabastine
Nude Mice
Northern Blotting
Binding Sites
SR 48692
Pancreatic Carcinoma
Inositol Phosphates
Cell Count
Calcium

Keywords

  • neurotensin
  • neurotensin receptor antagonist
  • pancreatic carcinoma
  • SR48692

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. / Iwase, Kazuhiro; Evers, B. Mark; Hellmich, Mark; Kim, Hong Jin; Higashide, Shunichi; Gully, Danielle; Thompson, James C.; Townsend, Courtney.

In: Cancer, Vol. 79, No. 9, 01.05.1997, p. 1787-1793.

Research output: Contribution to journalArticle

Iwase, Kazuhiro ; Evers, B. Mark ; Hellmich, Mark ; Kim, Hong Jin ; Higashide, Shunichi ; Gully, Danielle ; Thompson, James C. ; Townsend, Courtney. / Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. In: Cancer. 1997 ; Vol. 79, No. 9. pp. 1787-1793.
@article{24dd3f98f4b744e8a47145974bbcc3c0,
title = "Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692",
abstract = "BACKGROUND. Recently, a nonpeptide neurotensin (NT) receptor antagonist, SR48692, was developed that selectively antagonizes the high affinity, biologically active NT binding site. The effect of SR48692 on NT-mediated growth of a human pancreatic carcinoma, MIA PaCa-2, was determined both in vitro and in vivo. METHODS. 125I-NT binding and Northern blot analyses were performed for evaluation of the NT receptor in MIA PaCa-2 cells. Intracellular calcium ([Ca2+l(i)) mobilization and inositol phosphate (IP3) levels were measured. Cell growth studies were performed by counting cell numbers. Athymic nude mice were inoculated with MIA PaCa-2 cells and randomized into four groups to receive either vehicle (NT or SR48692) or NT + SR48692. RESULTS. MIA PaCa-2 cells possess both a high affinity, SR48692- sensitive and a levocabastine-insensitive NT binding site; Northern blot analysis demonstrated expression of the NT receptor. SR48692 inhibited [Ca2+](i) mobilization, IP3 turnover, and MIA PaCa-2 cell growth induced by NT in a dose-dependent fashion. In in vivo experiments, NT significantly increased the size, weight, and DNA and protein content of xenografted MIA PaCa-2 tumors; SR48692 inhibited the effect of NT. CONCLUSIONS. The novel NT receptor antagonist SR48692 will be a valuable agent to delineate further the cellular mechanisms responsible for peptide-mediated growth of normal and neoplastic gut tissues.",
keywords = "neurotensin, neurotensin receptor antagonist, pancreatic carcinoma, SR48692",
author = "Kazuhiro Iwase and Evers, {B. Mark} and Mark Hellmich and Kim, {Hong Jin} and Shunichi Higashide and Danielle Gully and Thompson, {James C.} and Courtney Townsend",
year = "1997",
month = "5",
day = "1",
doi = "10.1002/(SICI)1097-0142(19970501)79:9<1787::AID-CNCR22>3.0.CO;2-T",
language = "English (US)",
volume = "79",
pages = "1787--1793",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692

AU - Iwase, Kazuhiro

AU - Evers, B. Mark

AU - Hellmich, Mark

AU - Kim, Hong Jin

AU - Higashide, Shunichi

AU - Gully, Danielle

AU - Thompson, James C.

AU - Townsend, Courtney

PY - 1997/5/1

Y1 - 1997/5/1

N2 - BACKGROUND. Recently, a nonpeptide neurotensin (NT) receptor antagonist, SR48692, was developed that selectively antagonizes the high affinity, biologically active NT binding site. The effect of SR48692 on NT-mediated growth of a human pancreatic carcinoma, MIA PaCa-2, was determined both in vitro and in vivo. METHODS. 125I-NT binding and Northern blot analyses were performed for evaluation of the NT receptor in MIA PaCa-2 cells. Intracellular calcium ([Ca2+l(i)) mobilization and inositol phosphate (IP3) levels were measured. Cell growth studies were performed by counting cell numbers. Athymic nude mice were inoculated with MIA PaCa-2 cells and randomized into four groups to receive either vehicle (NT or SR48692) or NT + SR48692. RESULTS. MIA PaCa-2 cells possess both a high affinity, SR48692- sensitive and a levocabastine-insensitive NT binding site; Northern blot analysis demonstrated expression of the NT receptor. SR48692 inhibited [Ca2+](i) mobilization, IP3 turnover, and MIA PaCa-2 cell growth induced by NT in a dose-dependent fashion. In in vivo experiments, NT significantly increased the size, weight, and DNA and protein content of xenografted MIA PaCa-2 tumors; SR48692 inhibited the effect of NT. CONCLUSIONS. The novel NT receptor antagonist SR48692 will be a valuable agent to delineate further the cellular mechanisms responsible for peptide-mediated growth of normal and neoplastic gut tissues.

AB - BACKGROUND. Recently, a nonpeptide neurotensin (NT) receptor antagonist, SR48692, was developed that selectively antagonizes the high affinity, biologically active NT binding site. The effect of SR48692 on NT-mediated growth of a human pancreatic carcinoma, MIA PaCa-2, was determined both in vitro and in vivo. METHODS. 125I-NT binding and Northern blot analyses were performed for evaluation of the NT receptor in MIA PaCa-2 cells. Intracellular calcium ([Ca2+l(i)) mobilization and inositol phosphate (IP3) levels were measured. Cell growth studies were performed by counting cell numbers. Athymic nude mice were inoculated with MIA PaCa-2 cells and randomized into four groups to receive either vehicle (NT or SR48692) or NT + SR48692. RESULTS. MIA PaCa-2 cells possess both a high affinity, SR48692- sensitive and a levocabastine-insensitive NT binding site; Northern blot analysis demonstrated expression of the NT receptor. SR48692 inhibited [Ca2+](i) mobilization, IP3 turnover, and MIA PaCa-2 cell growth induced by NT in a dose-dependent fashion. In in vivo experiments, NT significantly increased the size, weight, and DNA and protein content of xenografted MIA PaCa-2 tumors; SR48692 inhibited the effect of NT. CONCLUSIONS. The novel NT receptor antagonist SR48692 will be a valuable agent to delineate further the cellular mechanisms responsible for peptide-mediated growth of normal and neoplastic gut tissues.

KW - neurotensin

KW - neurotensin receptor antagonist

KW - pancreatic carcinoma

KW - SR48692

UR - http://www.scopus.com/inward/record.url?scp=0030988580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030988580&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19970501)79:9<1787::AID-CNCR22>3.0.CO;2-T

DO - 10.1002/(SICI)1097-0142(19970501)79:9<1787::AID-CNCR22>3.0.CO;2-T

M3 - Article

VL - 79

SP - 1787

EP - 1793

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -